References
- Zhang L., Zhang Z. G., Zhang R. L., Lu M., Adams J., Elliott P. J., Chopp M. Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 2001; 32(12)2926–2931, [PUBMED], [INFOTRIEVE]
- Elliott P. J., Pien C. S., McCormack T. A., Chapman I. D., Adams J. Proteasome inhibition: a novel mechanism to combat asthma. J. Allergy Clin. Immunol. 1999; 104(2 Pt. 1)294–300, [PUBMED], [INFOTRIEVE], [CSA]
- Kawakami A., Nakashima T., Sakai H., Hida A., Urayama S., Yamasaki S., Nakamura H., Ida H., Ichinose Y., Aoyagi T., Furuichi I., Nakashima M., Migita K., Kawabe Y., Eguchi K. Regulation of synovial cell apoptosis by proteasome inhibitor. Arthritis Rheum. 1999; 42(11)2440–2448, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Masdehors P., Omura S., Merle-Beral H., Mentz F., Cosset J.-M., Dumont J., Magdelenat H., Delic J. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactyacystin. Br. J. Haematol. 1999; 105(3)752–757, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]